Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Jan 21, 2010

Premium

Title: Compositions and Methods for siRNA Inhibition of HIF-1 Alpha

Patent Number: 7,645,744

Filed: Jan. 26, 2009

Lead Inventor: Samuel Reich, University of Pennsylvania (Opko Health)

The patent, its abstract states, claims "RNA interference using small interfering RNAs [that] target HIF-1 alpha mRNA [to] inhibit expression of the HIF-1 alpha gene. As HIF-1 alpha is a transcriptional regulator of VEGF, expression of VEGF is also inhibited. Control of VEGF production through siRNA-mediated down-regulation of HIF-1 alpha can be used to inhibit angiogenesis, particularly in diseases such as diabetic retinopathy, age-related macular degeneration, and many types of cancer."


Title: siRNA Targeting Spleen Tyrosine Kinase

Patent Number: 7,645,869

Filed: Dec. 4, 2006

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes."


Title: siRNA Targeting Proteasome 26S Subunit, Non-ATPase, 10

Patent Number: 7,645,870

Filed: June 8, 2007

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to PSMD10."


Title: Treatment of Heart Failure

Application Number: 20100008908

Filed: April 2, 2009

Lead Inventor: Houman Ashrafian, Isis Innovation

The patent application, its abstract states, claims the "treatment of heart failure by administering a therapeutically effective amount of an agent that inhibits hypoxia-inducible factor. Such agents include small-molecule chemical agents and biological agents," including siRNAs or microRNAs.


Title: Targeted Delivery to Leukocytes Using Non-Protein Carriers

Application Number: 20100008937

Filed: April 25, 2007 PCT Filed: April 25, 2007

Lead Inventor: Dan Peer, Immune Disease Institute

The patent application, its abstract states, claims "delivery agents for selective delivery to leukocytes. The leukocyte-selective delivery agents comprise a targeting moiety that selectively binds LFA-I, a non-protein carrier moiety covalently linked to the targeting moiety, and a therapeutic agent associated with the carrier moiety. The non-protein carrier moiety comprises a liposome, a micelle, or a polymeric nanoparticle comprised of PLA or PLGA.

"The delivery agent may be further selective for activated leukocytes by using a targeting moiety that selectively binds LFA-I in its activated conformation," the abstract notes. "The targeting moiety may comprise an antibody or functional fragment thereof such as an scFV. Appropriate therapeutic agents include a nucleic acid, a small molecule, a polypeptide, and an antibody or functional fragment thereof. Additional examples of therapeutic agents are a small RNA, an antagomir, an LNA, or an antisense oligonucleotide. … Methods for in vivo, in vitro, and ex vivo leukocyte-selective delivery using the delivery agents are also disclosed."


Title: Methods and Sequences to Suppress Primate Huntington Gene Expression

Application Number: 20100008981

Filed: Sept. 10, 2009

Lead Inventor: William Kaemmerer, Medtronic

The invention, the patent application's abstract states, comprises "sequences, molecules, and methods used to suppress the expression of [Huntington's disease] genes encoding for huntingtin protein in primates including Macaca mulatto and Homo sapiens. These sequences, molecules, and methods aid in the study of the pathogenesis of HD and can also provide a treatment for this disease."


Title: microRNAs and Their Methods of Use for the Treatment and Diagnosis of Schizophrenia and Schizophrenia Spectrum Disorders

Application Number: 20100009367

Filed: June 12, 2009

Lead Inventor: Steve Sommer, City of Hope

The invention, the patent application's abstract states, comprises "a method of diagnosing, assessing susceptibility, and/or treating schizophrenia involving the identification and/or observation of microRNAs and variant miRNA. … [microRNA] alleles associated with schizophrenia and schizophrenia spectrum disorders were identified and ultra-rare variants in the precursor or mature miRNA were identified. Functional analyses of ectopically expressed copies of the variant miRNA precursors demonstrate loss of function, gain of function, and altered expression levels. The … invention also provides methods for selecting a preferred therapy for a particular subject or group of subjects or individuals at risk for or suffering from schizophrenia or psychosis by use of miRNAs."


Title: Biologically Active Molecules, Particularly Based on PNA and siRNA, Method for the Cell-Specific Activation Thereof, and Application Kit to Be Administered

Application Number: 20100009446

Filed: Feb. 13, 2008 PCT Filed: Feb. 13, 2008

Lead Inventor: Tobias Poehlmann, University of Jena

"Biologically active molecules are inactivated for selective activation by target cells by being covalently bonded to one or more peptides each of which has one or more specific amino acid sequences that are selected in respect of enzymes cell-specific for target cells," the patent application's abstract states. "The bonds, which are broken exclusively by the enzymes cell-specific for the target cells in order to biologically activate the molecules, allow the molecules to remain biologically inactive in cells other than the target cells. The molecules are used for influencing gene expression of preferably sick and infected organs or cells, for example."


Title: Compositions and Methods for Specifically Silencing a Target Nucleic Acid

Application Number: 20100009451

Filed: May 29, 2009

Lead Inventor: Erik Eastlund, Sigma-Aldrich

The invention, the patent application's abstract states, provides "methods modified oligonucleotides and methods of using the modified oligonucleotides for silencing nucleic acids, wherein the nonspecific effects of nucleic acid silencing are reduced."


Title: Randomized DNA Libraries and Double-Stranded RNA Libraries, Use, and Method of Production Thereof

Application Number: 20100009856

Filed: June 23, 2003 PCT Filed: June 23, 2003

Lead Inventor: Zicai Liang, Sinogenomax

"This invention relates to DNA libraries based on plasmid or viral vectors that can express double-stranded RNA of 10 [to] 30 base pairs in length with all possible sequences, where each of the double-stranded RNA is formed by a single RNA molecule in the form of hairpin, or formed by two separate RNA molecules with different 3' overhangs," the patent application's abstract states. "Each single member in such a DNA library encodes all components of a double-stranded RNA as specified above. Such a library can be used in screening for double-stranded RNA species that can induce a given phenotype without prior knowledge of their target genes. This invention further relates to a method to generate such a DNA library."


Title: microRNA Biomarkers for Human Breast and Lung Cancer

Application Number: 20100010072

Filed: May 6, 2009

Lead Inventor: Ethan Dmitrovsky, University of Copenhagen (Dartmouth College)

The invention "relates to novel molecular markers for diagnosis and classification of human breast cancer and lung cancer," the patent application's abstract states.


Title: microRNA for the Diagnosis and Treatment of Heart Diseases

Application Number: 20100010073

Filed: Oct. 9, 2007 PCT Filed: Oct. 9, 2007

Lead Inventor: Thomas Thum, University of Wurzburg

"The invention relates to microRNAs for the diagnosis, prophylaxis, and/or treatment of heart diseases," the patent application's abstract states. "In addition, the invention relates to the use of these sequences to produce a medicament for heart diseases and for the diagnosis thereof. Also encompassed are a method for the diagnosis of a heart disease, a kit and an expression vector comprising [certain] sequences, a cell which contains the expression vector, and … a method for modulating a heart disease and a method for screening a pharmaceutically active compound for the treatment and/or prophylaxis of a heart disease."


Title: siRNA Targeting Hypoxia-Inducible Factor 1

Application Number: 20100010206

Filed: Aug. 4, 2009

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed."


Title: RNA Interference-Mediating Small RNA Molecules

Application Number: 20100010207

Filed: Aug. 7, 2009

Lead Inventor: Thomas Tuschl, Max Planck

"Double-stranded RNA induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference," the patent application's abstract states. "Using a Drosophila in vitro system, we demonstrate that 19-23 [nucleotide long] short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3' ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex."


Title: Nanoparticles for Nucleic Acid Delivery

Application Number: 20100015232

Filed: July 6, 2007 PCT Filed: July 6, 2007

Lead Inventor: Flemming Besenbacher, Aarhus University

The invention "provides chitosan/RNA nanoparticles that are useful as research tools or medicaments," the patent application's abstract states. "Preferably, the RNA part of the nanoparticle is a siRNA capable of modulating the expression of a target mRNA. The invention also provides methods for the preparation of chitosan/RNA nanoparticles."


Title: Method for Constructing microRNA Adenovirus-Expression Plasmids of Severe Hepatitis Related HFGL2, HFAS, and HTNFR1 Genes and Pharmaceutical Use Thereof

Application Number: 20100015669

Filed: Nov. 12, 2008

Lead Inventor: Qin Ning

The invention, the patent application's abstract states, comprises "a method for constructing microRNA adenovirus-expression plasmids [made of] severe hepatitis related genes of hfgl2, prothrombinase, Fas, and TNFR1. … The specificity and [efficacy of the] microRNA interference plasmids are detected at cellular level so that a combined use of three microRNA adenovirus expression plasmids for the treatment of severe hepatitis can be achieved."


Title: Nucleic Acid Compounds for Inhibiting HIF1A Gene Expression and Uses Thereof

Application Number: 20100015706

Filed: Feb. 28, 2008 PCT Filed: Feb. 28, 2008

Lead Inventor: Steven Quay, MDRNA

The patent application, its abstract states, claims "meroduplex ribonucleic acid molecules capable of decreasing or silencing HIF1A gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a HIF1A mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside is a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a HIF1A gene in a cell or in a subject to treat a HIF1A-related disease."


Title: Short Interfering Ribonucleic Acid for Oral Administration

Application Number: 20100015707

Filed: May 2, 2007 PCT Filed: May 2, 2007

Inventor: Francois Jean-Charle Natt, Novartis

The patent application, according to its abstract, claims "short interfering ribonucleic acid for oral administration. … [The] siRNA [comprises] two separate RNA strands that are complementary to each other over at least 15 nucleotides, wherein each strand is 49 nucleotides or less, and wherein at least one of which strands contains at least one chemical modification."


Title: Ribonucleic Acids with Non-Standard Bases and Uses Thereof

Application Number: 20100015708

Filed: June 18, 2009

Lead Inventor: Steven Quay, MDRNA

The invention, the patent application's abstract states, comprises "a ribonucleic acid [with] a double-stranded region having at least one base pair comprising a 5-methyluridine base paired with a 2,6-diaminopurine and methods for preparing the same. Also provided are methods for treating or preventing a disease or disorder by inducing RNAi."


Title: siRNA Targeting Histamine Receptor H1

Application Number: 20100016176

Filed: Aug. 10, 2009

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed."


Title: Compositions and Methods for Inhibiting Expression of the MYC Gene

Application Number: 20100016405

Filed: July 9, 2007

Lead Inventor: David Bumcrot, Alnylam Pharmaceuticals

"The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of the MYC gene comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length … and which is substantially complementary to at least a part of the MYC gene," the patent application's abstract states. "The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by MYC gene expression, and the expression of the MYC gene using the pharmaceutical composition."


Title: Method of Modulation of Expression of Epidermal Growth Factor Receptor Involving miRNA

Application Number: 20100016411

Filed: Aug. 28, 2007 PCT Filed: Aug. 28, 2007

Lead Inventor: Peter Leedman, Western Australian Institute for Medical Research

The invention, the patent application's abstract states, "relates to a method for modulating the expression of epidermal growth factor receptor and its downstream signaling effectors. In particular, the … invention relates to a method for modulating the expression of epidermal growth factor receptor or like molecule in a cell comprising contacting said cell with an agent capable of directly or indirectly interacting with the 3'-untranslated region of the mRNA of said EGFR or like molecule, wherein the UTR is encoded by a sequence which comprises a sequence having at least about 70 [percent] identity with at least one sequence selected from the group consisting of [predefined] sequences."


Title: Targets for Human microRNAs in Avian Influenza Virus Genome

Application Number: 20100016414

Filed: July 8, 2009

Lead Inventor: Samir Kumar Brahmachari, Council of Scientific Affairs and Industrial Research

The invention, the patent application's abstract states, "relates to targets for human microRNAs in [the] avian influenza virus genome and provides specific miRNA targets against H5N1 virus."


Title: siRNA Targeting Cyclin-Dependent Kinase Inhibitor 1B

Application Number: 20100016573

Filed: Sept. 14, 2009

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CDKN1B."

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.